| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/05/1999 | CA2147836C Method for enhancing bioavailability of beta-carotene |
| 10/01/1999 | CA2249043A1 Novel compounds |
| 09/30/1999 | WO1999049316A2 Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 09/30/1999 | WO1999049039A2 GFRα3 AND ITS USES |
| 09/30/1999 | WO1999049027A1 Methods for prevention and treatment of cancer |
| 09/30/1999 | WO1999049023A1 The cytokine family member 2-21 |
| 09/30/1999 | WO1999049018A1 Glycosyl sulfotransferase-3 |
| 09/30/1999 | WO1999048536A2 Delivery of long lasting therapeutic agents by forming covalent attachments in vivo |
| 09/30/1999 | WO1999048530A1 Combination therapy for the treatment of benign prostatic hyperplasia |
| 09/30/1999 | WO1999048527A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 09/30/1999 | WO1999048523A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 09/30/1999 | WO1999048504A1 Compositions for inhibiting human immunodeficiency virus using hydroxyurea and a reverse transcriptase inhibitor |
| 09/30/1999 | WO1999048503A1 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate |
| 09/30/1999 | WO1999048500A1 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator |
| 09/30/1999 | WO1999048488A2 Methods for decreasing beta amyloid protein |
| 09/30/1999 | WO1999048485A1 Method of treating neuroma pain |
| 09/30/1999 | WO1999048484A2 Use of cabergoline in the treatment of restless legs syndrome |
| 09/30/1999 | WO1999048461A2 Substituted aromatic compounds for treatment of antibiotic resistant infections |
| 09/30/1999 | WO1999048371A1 Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors |
| 09/30/1999 | WO1999041411A3 Method for diagnosis and treatment of disorders of carbohydrate metabolism |
| 09/30/1999 | WO1999041387A3 Prostate-associated serine protease |
| 09/30/1999 | WO1999040945A3 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
| 09/30/1999 | WO1999039741A3 Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| 09/30/1999 | WO1999038532A3 Methods for the prevention and treatment of fibrosis and sclerosis |
| 09/30/1999 | WO1999037788A3 Diagnosis and treatment of aur1 and/or aur2 related disorders |
| 09/30/1999 | WO1999035277A3 Recombinant, active caspases and uses thereof |
| 09/30/1999 | WO1999035266A3 Human urotensin ii |
| 09/30/1999 | WO1999035246A9 Novel steroid-activated nuclear receptors and uses therefor |
| 09/30/1999 | WO1999029308A3 Method for combating obesity |
| 09/30/1999 | DE19906034A1 High-purity squalane useful in cosmetic and pharmaceutical products, as vaccine adjuvant, for coating condoms and hypodermic needles, etc. |
| 09/30/1999 | CA2325689A1 Substituted aromatic compounds for treatment of antibiotic resistant infections |
| 09/30/1999 | CA2325585A1 Inflammatory mediator antagonists |
| 09/30/1999 | CA2324999A1 Methods for decreasing .beta.-amyloid protein |
| 09/30/1999 | CA2324610A1 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate |
| 09/30/1999 | CA2324494A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 09/30/1999 | CA2323782A1 Methods for prevention and treatment of cancer |
| 09/30/1999 | CA2322779A1 Glycosyl sulfotransferase-3 |
| 09/30/1999 | CA2320204A1 Use of cabergoline in the treatment of restless legs syndrome |
| 09/30/1999 | CA2291066A1 Local delivery of long lasting therapeutic agents |
| 09/29/1999 | EP0945133A1 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| 09/29/1999 | EP0944828A1 Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption |
| 09/29/1999 | EP0944724A1 USE OF A VECTOR EXPRESSING DNA POLYMERASE $g(b) AS MEDICINE |
| 09/29/1999 | EP0944721A1 Adipocyte-specific differentiation-related protein |
| 09/29/1999 | EP0944720A1 Adaptor protein frs2 and related products and methods |
| 09/29/1999 | EP0944715A1 Pressure-mediated intracellular delivery of molecules or microparticles |
| 09/29/1999 | EP0944647A1 Submucosa extracts |
| 09/29/1999 | EP0944621A1 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists |
| 09/29/1999 | EP0944394A1 Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity |
| 09/29/1999 | EP0944309A1 Compositions for modulating intracellular inositol trisphosphate concentration and uses thereof |
| 09/29/1999 | EP0865274B1 Surface-stabilised pharmaceutical preparation for application on the skin |
| 09/29/1999 | CN1230122A Medical compsns. |
| 09/29/1999 | CN1230121A Means for treating prostate hypertrophy and prostate cancer |
| 09/29/1999 | CN1230120A Compounds that inhibit interaction between signal-transducing proteins and GLGF(PDZ/DHR) domain and uses thereof |
| 09/29/1999 | CN1230114A Novel treatment of leptine resistance |
| 09/29/1999 | CN1230110A Cell adhesion inhibitors |
| 09/29/1999 | CN1229677A Composition and methods using nitroxides to avoid oxygen toxicity |
| 09/28/1999 | US5959079 CREBA isoform |
| 09/28/1999 | US5959075 Testis-specific insulin homolog polypeptides |
| 09/28/1999 | US5958971 Chemical compounds |
| 09/28/1999 | US5958961 Pharmaceutical composition for angiotensin II-mediated diseases |
| 09/28/1999 | US5958959 Administering 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)anilide or 2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)-2-butenamide |
| 09/28/1999 | US5958933 Having a guanidino group aliphatically linked to a xanthine group, adrenergic stimulants |
| 09/28/1999 | US5958926 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 09/28/1999 | US5958902 Method and composition for treating sleep apnea |
| 09/28/1999 | US5958901 Delivery of anionic macromolecules into cells. |
| 09/28/1999 | US5958884 Compositions and methods for treating erectile dysfunction |
| 09/28/1999 | US5958880 Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof |
| 09/28/1999 | US5958731 Cell junction PDZ protein |
| 09/28/1999 | US5958725 Human DP1 homolog |
| 09/28/1999 | US5958720 Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same |
| 09/28/1999 | US5958711 Contacting a sample from a subject with an agent specific for said complex and determining interaction between said complex and said agent as a determination of said disorder |
| 09/28/1999 | US5958710 The receptor may be useful in isolating molecules for the treatment of disorders such as prostate cancer, benign prostatic hyperplasia, osteoporosis or cardiovascular disorders and in the testing of substances for estrogenic and |
| 09/28/1999 | US5958709 Processes for identifying compounds that bind to the human Y4 receptor |
| 09/28/1999 | US5958683 Screening method using the RZR receptor family |
| 09/28/1999 | US5958682 Virus-directed enzyme prodrug therapy for treating tumor cells consisting of a viral vector encoding bacterial nitroreductase capable of converting a prodrug into a cytotoxic drug operably linked to a promoter; and the prodrug |
| 09/28/1999 | US5958436 Formulations and methods for reducing skin irritation |
| 09/28/1999 | US5958432 Cosmetic/pharmaceutical compositions comprising β-adrenergic agonists/substance P antagonists |
| 09/28/1999 | US5958429 Potentiation of serotonin response |
| 09/28/1999 | US5958426 Sphingolipids and a process thereto |
| 09/28/1999 | US5958408 Glycosylation of lysin residue of a clearing agent which is an antibody or an antigen binding fragment of an antibody with a galactose residue for achieving fast clearance |
| 09/28/1999 | US5958405 Human protein tyrosine kinase |
| 09/28/1999 | US5958400 Isolated polypeptide comprising specified amino acid sequence |
| 09/28/1999 | US5958379 Drug is transported to the site of action within a very short time by means of the corresponding body liquid, particularly by means of blood, in order to systemically cause the desired effect |
| 09/28/1999 | US5957960 Internal two photon excitation device for delivery of PDT to diffuse abnormal cells |
| 09/28/1999 | CA2133503C Orally administrable opioid formulations having extended duration of effect |
| 09/28/1999 | CA2017029C Composition |
| 09/24/1999 | CA2249660A1 Novel compounds |
| 09/23/1999 | WO1999047703A1 Method for producing agents for treating tumour diseases and for immunosuppression |
| 09/23/1999 | WO1999047677A2 Polypeptides homologous to vegf and bmp1 |
| 09/23/1999 | WO1999047670A1 Mammalian sodium channel proteins |
| 09/23/1999 | WO1999047554A1 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| 09/23/1999 | WO1999047553A2 Bacterial yeal family members as targets for antimicrobial drug design |
| 09/23/1999 | WO1999047544A1 nrdF |
| 09/23/1999 | WO1999047537A1 Staphylococcus aureus spo0j2: polynucleotide and protein |
| 09/23/1999 | WO1999047535A1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS |
| 09/23/1999 | WO1999047178A1 Novel complementing receptor-ligand pairs and adoptive immunotherapy using same |
| 09/23/1999 | WO1999047173A2 Carrier for in vivo delivery of a therapeutic agent |
| 09/23/1999 | WO1999047171A1 Combination of a gaba-a alpha 5 inverse agonist and a muscarinic agonist |
| 09/23/1999 | WO1999047170A1 Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists |
| 09/23/1999 | WO1999047169A1 Methods to provoke anti-cancer immune responses |